




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION OF: Suggy S. Chrai

SERIAL NO: 09/774,346

GROUP ART UNIT: 1616

FILED: January 31, 2001

EXAMINER: Michael
Williamson

CUSTOMER NO.: 27162

FOR: Pharmaceutical Product and Method of Making

ATTY/DKT NO.: 176650-96

Box AF
Commissioner for Patents
Washington, D.C. 20231

Amendment Transmittal Letter

Dear Sir:


Transmitted herewith is an amendment in response to the Office Action of September 4, 2001, in the above case. The fee due, if any, has been calculated as follows:

	Claims After Amendment		Highest No. Paid For		Extra		Rate Fee		Addl.
Total	32	-	30	=	2	x	18	=	\$36.00
Indep.	7	-	5	=	2	x	84	=	<u>168.00</u>
Total Additional Fee.....									= \$204.00

Enclosed is a check in the amount of \$204.00 for the additional claims.


The Commissioner is authorized to charge any required fees for this paper not

accompanying this communication and to credit any overpayment to Deposit Account No.
03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Box AF Commissioner for Patents Washington, DC 20231	
 William Squire, Esq.	<u>Oct. 25, 2002</u> Date

#158769

Respectfully submitted,
Suggy S. Chrai



William Squire, Esq.

Reg. No. 25,378

Attorney for Applicants

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN

6 Becker Farm Road

Roseland, NJ 07068

Tel. No.: (973) 994-1700

Fax No.: (973) 994-1744

Email: wsquire@carellabyrne.com



EXPEDITED PROCEDURE
AFTER FINAL REJECTION
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Suggy S. Chrai
SERIAL NO. : 09/774,346
FILED : January 31, 2001
FOR : Pharmaceutical Product
and Method of Making
EXAMINER : Michael A. Williamson
ART UNIT: : 1616
ATTORNEY DOCKET: 176650-96

RECEIVED
NOV 01 2002
TECH CENTER 1600/2800

AMENDMENT UNDER 37 CFR 1.116

Box AF
Commissioner for Patents
Washington, DC 20231

Sir:

This paper is in response to the Office Action dated August 27, 2002 having a response due date set to expire on November 27, 2002.

IN THE CLAIMS

Amend the claims as follows:

21 (Twice amended). A product comprising a pharmaceutical or diagnostic unit form, the unit form comprising:

a first base substrate film comprising a first polymer;
a first deposit, including an active ingredient deposited on a first surface of said first base substrate film and forming a self contained complete single spaced discrete unit as deposited; and

10/31/2002 AWONDAF1 00000057 09774346

01 FC:1201
02 FC:1202

168.00 OP
36.00 OP